| Literature DB >> 35457168 |
Qianqian Wang1, Linyan Duan1, Xingfan Li1, Yifu Wang1, Wenna Guo1, Fangxia Guan1,2,3, Shanshan Ma1,2,3.
Abstract
Alzheimer's disease (AD), an elderly neurodegenerative disorder with a high incidence and progressive memory decline, is one of the most expensive, lethal, and burdening diseases. To date, the pathogenesis of AD has not been fully illustrated. Emerging studies have revealed that cellular senescence and abnormal glucose metabolism in the brain are the early hallmarks of AD. Moreover, cellular senescence and glucose metabolism disturbance in the brain of AD patients may precede amyloid-β deposition or Tau protein phosphorylation. Thus, metabolic reprogramming targeting senescent microglia and astrocytes may be a novel strategy for AD intervention and treatment. Here, we recapitulate the relationships between neural cell senescence and abnormal glucose metabolism (e.g., insulin signaling, glucose and lactate metabolism) in AD. We then discuss the potential perspective of metabolic reprogramming towards an AD intervention, providing a theoretical basis for the further exploration of the pathogenesis of and therapeutic approach toward AD.Entities:
Keywords: Alzheimer’s disease; glucose metabolism; metabolic reprogramming; neural cell senescence; therapeutics
Mesh:
Substances:
Year: 2022 PMID: 35457168 PMCID: PMC9030802 DOI: 10.3390/ijms23084351
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208